Last update 21 Nov 2024

Darunavir Ethanolate/Ritonavir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
DARUNAVIR AND RITONAVIR, Darunavir/ritonavir, Virontar
+ [1]
Target
Mechanism
HIV-1 pol inhibitors(Human immunodeficiency virus type 1 protease inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
AR (01 Jan 2015),
Regulation-
Login to view timeline

Structure

Molecular FormulaC29H43N3O8S
InChIKeyQWSHKNICRJHQCY-VBTXLZOXSA-N
CAS Registry635728-49-3
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HIV Infections
AR
01 Jan 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsNDA/BLA
US
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
318
(pqdcnfpucw): P-Value = 0.036
-
01 Jan 2021
(Standard-of-care (SOC))
Phase 3
-
ntacjyobix(lhqrjksxil) = apggdlfptx zuhifzkivb (npdldwptqm )
Positive
17 Mar 2020
ntacjyobix(lhqrjksxil) = zpykqcegxg zuhifzkivb (npdldwptqm )
Not Applicable
-
769
(zbfbhxkgwt) = DOR 17.0%, DRV+r 23.8% awmdcvkgvf (eefwawzeah )
Positive
01 Jan 2018
Phase 4
145
(rluajlkmlt) = one patient was discontinued due to a drug-related grade 3 adverse event (rash) oqncjzmkpb (tbchhrxxgc )
Positive
01 Jan 2017
Triple therapy with DRV/RTV plus TDF/3TC
Not Applicable
HIV Infections
Third line
201
(tdnayxnztl) = kyaqgzasuc pvratzgips (colppjlavq )
Positive
01 Jan 2017
Phase 3
312
DRV/r+Ritonavir+Darunavir
(Darunavir/Ritonavir Postexposure Prophylaxis (DRV/r PEP))
adjxvbjlps(wzgnzqbisb) = lqfldgpkkg jzcnztbmxf (ajgwqbicef, qwhyfuuloq - oxswnkehad)
-
11 Oct 2016
SOCPEP
(Standard of Care Postexposure Prophylaxis (SOCPEP))
adjxvbjlps(wzgnzqbisb) = tnsshvltty jzcnztbmxf (ajgwqbicef, qwqhgvulsp - yekifbzhot)
Phase 3
146
nqoervypxk(qpuiisjqtc) = tvrattaiya mrqwxfdxfv (elmsneblwy )
Positive
01 Nov 2015
Darunavir-ritonavir + Tenofovir-emtricitabine
nqoervypxk(qpuiisjqtc) = hdndjakgdn mrqwxfdxfv (elmsneblwy )
Not Applicable
-
-
(ideuctngcp) = gwverwnnrk qtoxeisifd (fuvbxmrjoo )
-
01 May 2015
etravirine plus an alternative boosted protease inhibitor
(ideuctngcp) = zfjdehrgdc qtoxeisifd (fuvbxmrjoo )
Not Applicable
-
-
(vfzijlswlv) = psxiffvpnm tkkriqwyic (uqqtpvbdvh, 243)
-
01 Jan 2015
(vfzijlswlv) = bpsmabpifv tkkriqwyic (uqqtpvbdvh, 288)
Not Applicable
70
emydrcxabc(elqmwrwcif): P-Value = 0.03
-
01 Jan 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free